

(FILE 'HOME' ENTERED AT 09:23:31 ON 05 MAY 2004)

FILE 'CAPLUS, MEDLINE, USPATFULL, EUROPATFULL' ENTERED AT 09:23:50 ON 05
MAY 2004

L1 1072 S IMMUNOFERON OR AM3 OR GLYCOPHOSPHOPEPTICAL
L2 2 S L1 AND NIGELLA SATIVA

L2 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:627968 CAPLUS
 DOCUMENT NUMBER: 133:202992
 TITLE: **Glycophosphopeptical or Nigella sativa** seeds for asthma/allergy therapy that targets T-lymphocytes and/or eosinophils
 INVENTOR(S): Nassief, Nida Abdul-Ghani
 PATENT ASSIGNEE(S): Al-Jassim, Rawaa, Australia; Al-Kaisi, Ban; James, David
 SOURCE: PCT Int. Appl., 28 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000051580	A2	20000908	WO 2000-IB222	20000302
WO 2000051580	A3	20011018		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
GB 2348132	A1	20000927	GB 2000-5003	20000301
EP 1242102	A2	20020925	EP 2000-909548	20000302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
US 2002061841	A1	20020523	US 2001-944564	20010904
PRIORITY APPLN. INFO.:				
			GB 1999-4777	A 19990302
			GB 1999-13341	A 19990608
			WO 2000-IB222	W 20000302

AB A pharmaceutical composition for the treatment and/or prophylaxis of diseases caused by type I hypersensitivity reactions consisting essentially of **glycophosphopeptical**, or pure **Nigella Sativa** seeds, in a concentration which stimulate Th1 lymphocytes and selectively switch-off the eosinophilic airway inflammation. A method of treatment of allergy using Th1 stimulating agents, to be administered to a mammal such as human in need of such treatment in a shot of 5 days only, resulted in significant decrease in symptom score started day 3, and in sputum eosinophils by day 14, followed by long-term clin. remission of a mean of 6 mo. The BCG-like Th1 stimulation is also used in treating diseases in which the body defensive mechanism is a cell-mediated immunity, including viral infections, including influenza and common cold, chronic and recurrent urinary tract infection, pelvic inflammatory diseases as neuroimmune appendicitis, cancer, Crohn's disease and facial palsy.

L2 ANSWER 2 OF 2 USPATFULL on STN
 ACCESSION NUMBER: 2002:119853 USPATFULL
 TITLE: Asthma/allergy therapy that targets T-lymphocytes and/or eosinophils
 INVENTOR(S): Nassief, Nida Abdul-Ghani, Doha, IRAQ

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002061841	A1	20020523
APPLICATION INFO.:	US 2001-944564	A1	20010904 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-4777	19990302
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AL-JASSIM, Rawaa, 2578 River Woods Drive, Naperville, IL, 60565	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	772	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition for the treatment and/or prophylaxis of diseases caused by type I hypersensitivity reactions consisting essentially of Glicophosphopeptical, or pure **Nigella Sativa** seeds, in a concentration which stimulate Th1 lymphocytes and selectively switch-off the eosinophilic airway inflammation

A method of treatment of allergy using Th1 stimulating agents, to be administered to a mammal such as human in need of such treatment in a shot of 5 days only, resulted in significant decrease in symptom score started day 3, and in sputum eosinophils by day 14, followed by long-term clinical remission of a mean of 6 months.

The BCG-like Th1 stimulation is also used in treating diseases in which the body defensive mechanism is a Cell Mediated Immunity, including viral infections, as but not limited to influenza and common cold, Chronic and recurrent urinary tract infection, pelvic inflammatory diseases as neuroimmune appendicitis, cancer, crohns disease and facial palsy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>